CLINICAL STUDY

The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals

Philip W Peake, Adamandia D Kriketos1, Lesley V Campbell1, Yvonne Shen and John A Charlesworth

Division of Medicine, Prince of Wales Hospital, Randwick, New South Wales 2031, Australia and 1Garvan Institute of Medical Research, St Vincents Hospital, Darlinghurst, New South Wales 2010, Australia

(Correspondence should be addressed to P Peake; Email: P.Peake@unsw.edu.au)

Abstract

Objective: Little is known of the metabolism of different isoforms of adiponectin. We therefore (a) characterised the size distribution of human adiponectin in relation to gender, body composition and following a challenge with a fat meal or oral glucose in humans, and (b) studied the metabolism of isoforms of human adiponectin in rabbits.

Method: Electrophoresis, blotting and chromatography were used to characterise human adiponectin in 36 healthy subjects, including 15 with at least two first-degree relatives with type 2 diabetes, before and after consumption of a fatty meal or glucose. The metabolism of column-fractionated human adiponectin was studied in rabbits, some of which were coinjected with insulin.

Results: Females had a higher proportion of high molecular weight (HMW) and hexameric adiponectin (P = 0.002 and 0.004 respectively), and a lower proportion of trimers (P < 0.0001) than males. Females also showed a strong negative relationship between body fat measures and the proportion of HMW adiponectin. There were no differences in isoforms between insulin-resistant and -sensitive subjects, or following oral glucose or a fat meal. Adiponectin in rabbits had an extravascular/intravascular ratio of 0.71, and a half-life (T1/2) of 14.3 h. Metabolism was not influenced by insulin or reduction of sulphydryl bonds. HMW and trimeric isoforms had a significantly different T1/2 of 13.0 and 17.5 h respectively (P < 0.05), and these isoforms did not interconvert in vivo.

Conclusions: Human adiponectin is present as trimers, hexamers and HMW forms. Females had a higher proportion and absolute amount of HMW species compared with males, and female, but not male, subjects showed a strong negative relationship between measures of body fat, and the proportion of HMW species. These isoforms did not respond to challenge in man with a fatty meal or oral glucose, and in the rabbit, to injected insulin. HMW adiponectin was more rapidly metabolised than the trimeric form, but both were stable in vivo, and did not interconvert. We conclude that human adiponectin is much longer-lived than is the case with other hormones, a finding with positive implications for the potential to supplement levels of adiponectin in man.

European Journal of Endocrinology 153 409–417

Introduction

Adiponectin is an adipose-specific protein that circulates at high concentration in the plasma and is believed to enhance insulin sensitivity, and suppress hepatic glucose production (1). Insulin sensitising drugs such as thiazolidinediones significantly increase plasma adiponectin in both humans and rodents (2). Circulating levels also correlate negatively with the presence of cardiovascular disease in patients with type 2 diabetes (3), consistent with the hypothesis that this protein also acts as a protective factor for the cardiovascular system (4). Paradoxically, since the protein is produced only by fat tissue, levels of adiponectin also correlate negatively with adiposity (5).

Studies in mice also suggest that adiponectin plays a role in insulin resistance and fat metabolism. Adiponectin knockout mice have delayed clearance of plasma fatty acids (6), and may exhibit a moderate to severe degree of insulin resistance (6, 7). Supplementation of adiponectin in vivo leads to a reduction in serum glucose in the absence of increased insulin secretion (1). Furthermore, treatment of mice with a globular fragment of adiponectin significantly decreases the elevated levels of plasma free fatty acids caused by administration of a high fat test meal (8), while supplementation in vivo ameliorated atherosclerosis in apolipoprotein E-deficient mice (9, 10).

In man, adiponectin assembles into higher order structures (11), as do the related molecules C1q and
the mouse homologue Acrp30. However, the nature and function(s) of these isoforms have not been fully characterised, and their response to physiological stimuli remains unclear. In mice, levels of the high molecular weight (HMW) complex are significantly reduced in response to insulin or glucose gavage (12), while in man mutant forms of the molecule with impaired ability to multimerise have been linked to diabetes (13). However, in some assays monomers or a globular fragment are more biologically active than higher order structures (8, 12).

Because different isoforms of Acrp30 induce different physiological responses (12, 13), characterisation of the behaviour in vivo of these isoforms should aid interpretation of the established correlations between total levels of adiponectin and phenomena such as insulin resistance and cardiovascular protection (4, 14). It would also provide important information necessary before therapeutic supplementation of adiponectin in man is attempted. In this study we established a sensitive assay capable of characterising different isoforms of adiponectin in native human plasma and related these to gender and body composition. Two groups of subjects were investigated: (i) a clinically healthy control group with no family history of diabetes, and (ii) a similarly healthy group with significantly reduced insulin sensitivity. The latter group consisted of normoglycaemic subjects with at least two first-degree relatives with type 2 diabetes (‘relatives’). We then related variations in levels of multimers between groups and genders to body composition. We also examined whether oral glucose or a fat meal had any acute effects on isoform distribution.

Because of the favourable effects in mice of administration of adiponectin on fatty acid transport and vascular physiology, we then examined the metabolic behaviour of the native molecule and its high and low molecular weight isoforms in rabbits. The fractional catabolic rate and extravascular/intravascular distributions were calculated from plasma disappearance curves, and the generation of different isoforms was examined in relation to administration of i.v. insulin.

Materials and methods

Subjects

Thirty-six healthy, sedentary, non-smoking subjects (22 females/14 males) were included. They comprised a clinically healthy control group with no family history of diabetes, and relatives. There were no significant differences between females and males, or between the controls and relatives in terms of body mass index (BMI) or amount of central fat (kg) (Table 1). The St. Vincent’s Hospital Human Research Ethics Committee approved the study and all subjects gave written informed consent.

The protocols used to characterise the subjects and administer a fat meal and an oral glucose tolerance test have been reported previously in a study on a similar group of subjects (15, 16). Body composition was assessed by dual energy emission x-ray absorptiometry (DEXA) and whole-body insulin sensitivity by a 120-min euglycaemic, hyperinsulinaemic clamp. Subjects received an oral fat meal, containing approximately 80 g dietary fat with an energy content of 4250 kJ, while fifteen females from the normal population were given glucose (1 mg/g) orally over 5 min.

Blood analyses

Plasma glucose was determined using a YSI glucose analyser (YSI 2300 StatPlus; YSI, Yellow Springs OH, USA). Inter- and intra-assay coefficients of variation were <10%.

Adiponectin levels in samples from human subjects were measured by a commercial RIA (Linco, St Charles, MO, USA).

Electrophoretic analysis of adiponectin

To take advantage of its superior resolution, serum proteins were analysed by native electrophoresis in 5% acrylamide gels containing trisglycine buffer, pH 8.3, and 1 mM Ca\(^{++}\), followed by Western blotting. Blots were probed with a monoclonal antibody to adiponectin (BD Biosciences, Sydney, Australia), which was detected with an affinity purified, alkaline phosphatase-conjugated antibody to mouse immunoglobulin (Sigma, Sydney, Australia). These were scanned and analysed by Kodak Digital Science (New Haven CT) 1D image analysis software. Intra- and interassay coefficients of variation were \(\approx 11\%\) and 16% respectively. The absolute amount of adiponectin in each isoform was determined by multiplying the fraction present by the overall concentration of adiponectin.

Animal metabolic studies

Adult female New Zealand rabbits (2.5–3.5 kg in weight) were used in all experiments. To minimise protein denaturation, experiments were performed with serum from a single adult volunteer in good health, not on medication, with a BMI of 29 kg/m\(^2\).

Experimental protocol

The experimental protocol included the following groups: (1) five rabbits received 2 to 2.5 ml serum only; (2) five rabbits received 2 to 2.5 ml serum containing 2 U/kg Actrapid insulin; (3) six rabbits received up to 8 ml of a preparation of serum containing predominantly high molecular weight (HMW) isoforms of adiponectin; (4) six rabbits received up to 8 ml of a preparation of serum containing predominantly low molecular weight (LMW) isoforms of adiponectin; (5) two rabbits received a preparation of serum in which adiponectin had been fully reduced by incubation with dithiothreitol (DTT).
Subject characteristics. Data are expressed as mean±S.E.M.

<table>
<thead>
<tr>
<th></th>
<th>All subjects (n = 36)</th>
<th>Controls (n = 21)</th>
<th>Relatives (n = 15)</th>
<th>Male (n = 14)</th>
<th>Female (n = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>24.8±0.8</td>
<td>23.8±0.9</td>
<td>26.1±1.4</td>
<td>26.2±1.0</td>
<td>23.8±1.1</td>
</tr>
<tr>
<td>Adiponectin (µg/ml)</td>
<td>18.8±1.5</td>
<td>19.3±1.9</td>
<td>17.9±2.5</td>
<td>11.3±1.5</td>
<td>23.5±1.5†</td>
</tr>
<tr>
<td>GIR (µmole/min/kg FFM)</td>
<td>60.1±3.1</td>
<td>66.0±4.1</td>
<td>52.0±3.9*</td>
<td>65.0±5.7</td>
<td>57.0±3.5</td>
</tr>
<tr>
<td>Central abdominal fat (kg)</td>
<td>1.23±0.11</td>
<td>1.11±0.14</td>
<td>1.41±0.19</td>
<td>1.27±0.19</td>
<td>1.21±0.15</td>
</tr>
<tr>
<td>Central abdominal fat (%)</td>
<td>26.7±1.7</td>
<td>24.8±2.2</td>
<td>29.3±2.5</td>
<td>23.3±2.5</td>
<td>28.8±2.1</td>
</tr>
<tr>
<td>Fat (%)</td>
<td>29.4±1.8</td>
<td>27.1±2.2</td>
<td>32.3±2.7</td>
<td>23.1±2.4</td>
<td>33.8±2.0‡</td>
</tr>
</tbody>
</table>

*P = 0.02, †P < 0.001, ‡P = 0.002 for differences between controls and relatives, or males and females, as determined by unpaired t-test.
GIR, glucose infusion rate.

Serum was injected into a marginal ear vein. Blood samples in ethylene diaminotetraacetic acid were drawn from the contralateral ear at 10 min, and for up to 51 h post injection; i.e. until <8% remained in the plasma compartment. The University of New South Wales (UNSW) Animal Research Ethics Committee gave consent to these investigations.

Purification of adiponectin and its isoforms
Before injection, all samples of serum were equilibrated with sterile nonpyrogenic saline by passage through a G25 column. Fractions containing predominantly high or low molecular weight adiponectin were prepared by passage at 4°C of serum down a 2.5 × 90 cm column of Sephacryl S300 equilibrated with phosphate-buffered saline in pyrogen-free water.

Reduction of adiponectin
Serum was incubated with 0.1 M DTT for 60 min at 37°C.

Analysis of adiponectin
Adiponectin levels in samples from FPLC analyses and from rabbits injected with human adiponectin (see below) were measured by a sensitive monoclonal sandwich ELISA specific for human adiponectin (R&D Minneapolis, MN, USA). Interference in this assay by rabbit adiponectin was <1%. The concentration of the related molecule C1q was determined by a sandwich ELISA standardised against donor serum diluted in rabbit serum. Wells were coated with rabbit anti C1q (Dako Glostrup, Denmark), and bound C1q was detected with goat anti-human C1q (Cappel Irvine, CA, USA) diluted in 5% rabbit serum, followed by an alkaline phosphatase-conjugated monoclonal antibody to goat IgG (Sigma).

Sulphydryl group detection
Sulphydryl groups were detected with Iodoacetyl-LC-Biotin (Pierce Rockford, IL, USA) following the manufacturer's instructions.

Superose column chromatography
Adiponectin in plasma was resolved by chromatography on an FPLC Superose 12 column (Pharmacia) equilibrated with 0.05 M Tris buffer.

Statistical analysis
Comparisons between groups were performed using one-way ANOVA with Dunnett and Bonferroni post tests, and paired and unpaired t-tests. Relationships between continuous variables were assessed by two-tailed Pearson correlation analyses. Allowance was made for the potentially confounding effect on significance of multiple comparisons by reducing the threshold for acceptance according to the formula 1 − 0.95^1/n, where n is the number of hypotheses being tested. The amount of human adiponectin present in rabbit serum was plotted against time after injection, with the assumption that levels at 10 min represented 97% of the injected dose. The analysis of data was carried out by Matthews’ exponential analysis, by fitting of data to a two-phase exponential decay equation (GraphPad Prism San Diego, CA, USA), essentially as previously described (17). Results are presented as means±S.E.M.

Results
Subject characteristics
The age of the subjects was between 25 and 45 years with BMIs <35 kg/m² (Table 1). Control subjects had 27% higher insulin sensitivity than first degree relatives of patients with type 2 diabetes, but did not differ significantly in BMI or body fat composition (Table 1).

Adiponectin isoforms
Adiponectin in normal serum ranged in size from ~1000 kDa to species of ~200 kDa (Fig. 1a). The latter contained essentially all of the detectable free sulphydryl groups within adiponectin (Fig. 1a), and the distribution of reduced adiponectin was essentially identical. However, on removal of DTT, adiponectin was able to reassociate to a near normal distribution.
Correlation with subject characteristics

Following the approach of Pajvani et al. (18), adiponectin levels in the two HMW bands (1 and 2) were pooled as HMW adiponectin; levels of these varied together and showed similar correlations with body characteristics and gender. We confirmed the well-known sex differential in adiponectin levels between males and females (Table 1), and showed that females had a significantly higher proportion of HMW and hexameric adiponectin compared with males (0.32±0.01 vs 0.26±0.01, \( P = 0.002 \) and 0.39±0.01 vs 0.33±0.02, \( P = 0.004 \) respectively), but a significantly lower proportion of trimeric adiponectin (0.28±0.01 vs 0.41±0.02, \( P < 0.0001 \)). When absolute amounts of adiponectin were compared, levels of all isoforms were significantly greater in females than in males (HMW: 7.6±0.61 vs 3.0±0.5, \( P < 0.0001 \); hexamer: 9.2±0.6 vs 3.8±0.61, \( P < 0.0001 \); trimer: 6.6±0.5 vs 4.6±0.6, \( P = 0.01 \)).

When all subjects were considered, the proportion of HMW adiponectin was negatively correlated with BMI (\( r = -0.38, P \leq 0.02 \)), and with central abdominal fat (kg) (\( r = -0.34, P < 0.05 \)). Female, but not male, subjects showed a strong negative relationship between measures of body fat and the proportion of HMW isomers. Correlations between central abdominal fat (kg), central abdominal fat (%), and fat (%) for this group were \(-0.48, -0.49 \) and \(-0.52 \) respectively; \( P \leq 0.02 \) for each. Although the controls and relatives differed significantly in insulin sensitivity, there were no significant differences between these groups in terms of the concentration of serum adiponectin or the amount of adiponectin of any particular size. This was also true when males and females from each group were considered individually. There was also no relationship between insulin sensitivity in all subjects (range 24.3–111.4 μmol/min/kg fat-free mass (FFM)) and levels of adiponectin in total, or of the proportion of adiponectin in each isoform.

Postprandial response to a high fat meal

Postprandial values of triglyceride, insulin, non-esterified fatty acid and triglyceride were similar in the relatives of patients with diabetes and control subjects, and to those in similar studies using the same fat meal (15, 16). Glucose levels were essentially unchanged, and there was no significant difference (<5%) between the proportions of each adiponectin isomer present in basal and postprandial samples.

Response to an oral glucose tolerance test

In 15 female subjects from the normal population, mean levels of adiponectin did not change significantly, and the proportions of adiponectin present in each
isoform were unchanged (<6%) following an oral glucose tolerance test.

**In vivo behaviour of adiponectin**

Human adiponectin injected into rabbits showed an initial rapid fall in level, followed by a log-linear phase of slower decline (Fig. 2a). Reducing sodium dodecyl sulphate (SDS) analysis followed by Western blotting confirmed that the protein was circulating intact, with essentially no breakdown products. Analysis of the decay curve showed adiponectin has a mean fractional catabolic rate (FCR) of 8.7%/h, an extravascular: intravascular (ev/iv) ratio of 0.71, and a half-life (T1/2) of ~14 h (Table 2). These characteristics were unaffected by the coinjection of insulin (Fig. 2a), although levels of glucose declined from 6.6±0.2 to 3.8±0.6 1 h post injection, recovering to 4.7±0.4 mmol/l at 2 h.

**Treatment with DTT**

Following DTT treatment, the metabolic behaviour of reduced adiponectin was similar to that seen with normal serum (Fig. 2a), while the size distribution of the isoforms was similar to that seen in normal serum (see below).

**In vivo behaviour of high and low molecular weight forms of adiponectin**

Data from experiments on serum preparations enriched in HMW and LMW forms of adiponectin showed that the former had a significantly higher FCR and a shorter T1/2. However, the ev/iv ratios did not differ significantly (Fig. 2b, Table 2). The metabolic characteristics of the related molecule, C1q, were not significantly different to that of HMW adiponectin (Fig. 2b, Table 2).

**Size distribution of adiponectin in vivo**

By 2 h post injection in both control rabbits and those injected with insulin, the proportion of high molecular weight isoforms had significantly declined (fractions 4 and 5), while the proportion present as the trimer had significantly increased (fractions 10 and 12) (Fig. 3). However, there were no significant effects resulting from injection with insulin.

The semipurified LMW fraction predominantly consisted of trimers, and the relative distribution of this fraction did not change significantly for up to 31 h in vivo (Fig. 4a). Only 22% of the injected dose of the HMW preparation was present in fractions 9–13 at 10 min post injection, but this rose significantly so that at 31 h post injection, 37% of adiponectin was present in these fractions (Fig. 4b). However, allowance must be made for the lower fractional catabolic rate of low molecular weight adiponectin. The actual concentration of adiponectin present in fractions 9–13 is 3.0% of the injected dose, while the amount that would be predicted from consideration of the decay characteristics of the low molecular weight isoforms present at 10 min post injection is 3.9% (Table 2).

**Discussion**

In man, the physiochemical nature of adiponectin has not been fully characterised, and its response to physiological stimuli remains unclear. We showed that human adiponectin is present in size ranges that correspond to the trimers, hexamers and HMW forms described in mice (19), including two forms of HMW complexes not separable by conventional chromatography. The identification of the isoform with an apparent
molecular mass, under gel filtration, of 200 kDa as a trimer is consistent with published models of the mouse homologue, in which an elongated trimer contains a disulphide bond, and one accessible sulphydryl group. Reduction of sulphydryl groups collapsed all isoforms into trimers in mice (20) and in our studies of human subjects. Since we found no accessible sulphydryl groups in isoforms other than the trimer, these are most likely non-covalent associates of the disulphide-linked hexamer, rather than a mixture of hexamers and trimers.

Adiponectin isoforms appear stable in vivo in man, as the proportions and amount of each did not change after the ingestion of either a fatty meal or glucose. Similarly, when the metabolism of human adiponectin was studied in rabbits, the administration of insulin did not significantly affect its half-life or multimeric distribution. As well, adiponectin was relatively long-lived in comparison with other hormones, with an average half-life in the rabbit of approximately 14 h. This figure may be underestimated, as human proteins typically exhibit more rapid metabolism in the rabbit than in man. Thus C3, the third component of human complement, has a T1/2 in the rabbit of approximately 37 h, but 70 h in man (21). In comparison, rabbit C3 has a T1/2 of 29 h when reinjected into rabbits (21). The comparability of our data on the behaviour of the adiponectin-related molecule C1q in the rabbit to published turnover data on C1q in man (22, 23) supports our conclusions on the metabolic behaviour of adiponectin. These findings have positive implications for the potential to supplement levels of adiponectin in man, a procedure suggested because of

### Table 2

<table>
<thead>
<tr>
<th>isoform</th>
<th>Fractional rate (%/h)</th>
<th>Catabolic ev/iv</th>
<th>T1/2 (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adiponectin control (n = 5)</td>
<td>8.7±1.4</td>
<td>0.71±0.23</td>
<td>14.3±1.2</td>
</tr>
<tr>
<td>Adiponectin + 2 U/kg insulin (n = 5)</td>
<td>7.9±0.04</td>
<td>0.64±0.06</td>
<td>17.0±1.1</td>
</tr>
<tr>
<td>LMW adiponectin (n = 6)</td>
<td>6.6±0.5*</td>
<td>0.65±0.07</td>
<td>17.5±1.1*</td>
</tr>
<tr>
<td>HMW adiponectin (n = 6)</td>
<td>12.0±2.1*</td>
<td>1.08±0.38</td>
<td>13.0±0.9*</td>
</tr>
<tr>
<td>C1q (n = 6)</td>
<td>8.7±2.2</td>
<td>0.65±0.18</td>
<td>14.4±1.7</td>
</tr>
</tbody>
</table>

*P < 0.05 for differences between HMW and LMW adiponectin.
experimental demonstrations of its ability to protect against vascular disease and to increase insulin sensitivity (1, 9, 10). As well, the mean ev/v ratio of 0.71 indicates that approximately 42% of the total pool resides in the extracellular compartment, so that the rapid and significant changes in circulating levels reported in some studies (e.g. a fourfold increase in postprandial adiponectin within 60 min (24)) may reflect compartmental redistribution.

Individual isoforms of adiponectin induce different physiological responses (12, 13). Similarly, they displayed different metabolic characteristics; HMW forms had a mean T1/2 of 13.0 h that was significantly shorter than that of 17.5 h found for LMW. Nevertheless, these were stable in vivo under a variety of conditions despite the fact that in vitro adiponectin, reduced to the trimer, reassembled into a range of isoforms with similar size characteristics and metabolic behaviour to the native molecule. These findings differ from those in the mouse, where it has been proposed that reduction of the disulphide bond in the Acrp30 homologue is an important step in its activation to a short-lived trimeric form (12). The quantity and stability of the trimers detected in this study suggest this is not the case in man. In addition, HMW isoforms in mice had a longer T1/2 (9 h) than hexamers (4.5 h), but the recombinant preparation studied had been precipitated, then radio-labelled, by extended oxidation with chloramine-T. There was minimal in vitro manipulation of the preparations in our study, and the high Y-axis intercepts of the final exponentials of the plasma disappearance curves confirmed there was little denatured or rapidly cleared material present.

Although primarily concerned with metabolic behaviour, our data also show sexual dimorphism of adiponectin isoforms, with females having a significantly higher proportion of HMW and hexamers, and a significantly lower proportion of trimers. Females had significantly higher amounts of all isoforms, reflecting their higher absolute levels of adiponectin, as do female mice (12). It is possible these differences are related to the well-known differential between male and female in terms of fat distribution and metabolism (25), and the selective inhibition of the secretion of HMW adiponectin by testosterone (26).

Total adiponectin concentrations are negatively correlated with BMI (27), and our data suggest this depended largely upon the proportion of HMW adiponectin. In females, there were significant negative correlations between the proportion of HMW isomers and measures of body fat; correlations were not observed with the proportions of hexamers or trimers. Total adiponectin levels have been associated with insulin sensitivity (14, 27), and improved insulin sensitivity following thiazolidinedione treatment correlated with an increase in the proportion of HMW isomers (18), possibly resulting from a direct effect of thiazolidinedione on their synthesis; it was not seen in subjects treated with metformin (18). While significantly more insulin resistant than the control group, the relatives in this study did not differ in total adiponectin (28), or in the proportion of HMW isomers. However, a study of subjects with type II diabetes and a greater reduction in insulin sensitivity might be more powerful in detecting such a relationship.

Most studies of adiponectin in man have not shown short-term responses to a variety of stimuli, and these could be difficult to effect, given its high concentration and long half-life. Instead, its concentration appears to change only over a prolonged period of time, in response to changes in such parameters as body weight, hormone levels, and insulin sensitivity. The role of the various multimeric forms of adiponectin remains to be determined. Although receptors for both a globular fragment and full-length adiponectin have been described, the quantities we detected for each multimeric form would be sufficient to signal via the receptor for the full-length molecule, since the Kd for AdipoR2 is 0.8 μg/ml (29). This could suggest some property of the molecule other than just its multimeric status initiates receptor signalling in vivo, despite considerable data showing distinct physiological responses induced by different multimeric forms (12, 13). The role of posttranslational modifications such as glycosylation on the activity of the molecule remains to be fully elucidated (30, 31), as do variations in receptor number and type. Alternatively, it has recently been found that the various oligomeric complexes of adiponectin bind selectively to different growth factors, thus controlling their bioavailability and inflammatory potential at a pre-receptor level (32), and obviating the need for receptor interaction to induce a physiological response. These findings differ from those in mice, where it has been reported that levels of the HMW complex were significantly reduced in response to a systemic increase of insulin (12). Differences between mice and man in the metabolic roles of adiponectin isoforms may derive from differences such as those in the N terminal sequence, which is important in the formation of oligomers (13).

In summary, we showed that human adiponectin is present as trimers, hexamers and HMW forms. Females had a higher proportion and absolute amount of HMW species compared with males, and female, but not male, subjects showed a strong negative relationship between measures of body fat, and the proportion of HMW species. These isoforms did not respond to challenge in man with a fatty meal or oral glucose, and in the rabbit to injected insulin. HMW adiponectin was more rapidly metabolised than the trimeric form, but both were stable in vivo, and did not interconvert. With a mean T1/2 of 14.3 h, human adiponectin is much longer lived than is the case with other hormones, a finding with positive implications for the potential to supplement levels of adiponectin in man.
Acknowledgements

We gratefully acknowledge the technical assistance of Melissa Sam in this study.

References


Received 9 February 2005
Accepted 1 June 2005